Fatal rhabdomyolysis caused by lipid-lowering therapy
Related Experiment Video
Updated: Oct 3, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
Published on: March 29, 2024
D G Federman1, F Hussain, A B Walters
1Department of Medicine and the Pharmacy Service, VA Connecticut Health Care System, West Haven, CT 06516, USA.
Abstract:
Treatment of hypercholesterolemia has been shown to reduce mortality in patients with coronary artery disease. Patients with severe lipid abnormalities may require high-dose statin therapy, at times used in combination with additional agents. We report a case of fatal rhabdomyolysis caused by the combination of simvastatin and gemfibrozil. Clinicians should be aware of risk factors for rhabdomyolysis, which include underlying renal insufficiency, high-dose statin therapy, and combination therapy with a fibrate.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Nephrotic Syndrome I : Introduction
Hemodialysis II: Procedure and Complications
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug toxicity: Drug–Drug Interaction
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...